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Abstract
Background: Early diagnosis and effective treatment with an appropriate drug form the main
components of the World Health Organization's strategy to reduce malaria related mortality. The
few available drugs might be safeguarded if combined with artesunate. The addition of artesunate
to a standard antimalarial treatment substantially reduces treatment failure, recrudescence and
gametocyte carriage.
Methods: During late 2004, the efficacy of artesunate (4 mg/kg. day, on days 0–2) plus sulfadoxine-
pyrimethamine (25 mg/kg, on day 0) for the treatment of uncomplicated Plasmodium falciparum
malaria was investigated in four sentinel areas in Sudan, with different malaria transmission
(Damazin, Kassala, Kosti, and Malakal).
Results: Two hundreds and sixty-nine patients completed the 28-day follow-up. On day one, 60
(22.3%) patients were febrile and 15 (5.5%) patients were parasitaemic. On day three, all the
patients were afebrile and aparasitaemic. While two patients (0.7%, Kassala) showed late Clinical
and Parasitological Failures, the rest (99.3%) of the patients demonstrated Adequate Clinical and
Parasitological Response. A gametocytaemia were detected during the follow-up in one patient
(0.37%, Kassala). Adverse drug effects were detected in 32 (11.9%) patients
Conclusion: The study showed that AS plus SP is an effective, safe drug in the treatment of
uncomplicated P. falciparum malaria in Sudan.
Background
There are almost 515 (range 300–660) million episodes
of clinical Plasmodium falciparum malaria infections [1].
Drug-resistant malaria is spreading in Africa and countries
with high levels of resistance have witnessed increased
morbidity and mortality [2]. Early diagnosis and effective
treatment with an appropriate drug form the main com-
ponents of the World Health Organization's strategy to
reduce malaria-related mortality [3].
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The few available drugs might be safeguarded if combined
with artesunate. The addition of artesunate to standard
antimalarial treatments substantially reduces treatment
failure, recrudescence and gametocyte carriage, preventing
the emergence and spread of drug resistance and inter-
rupting the transmission of P. falciparum. Coupled with
early detection and confirmed diagnosis, this strategy rep-
resents the only way forward in the chemotherapy of
malaria [4-8].
Malaria causes between 7.5 to 10 million cases and
35,000 deaths every year in Sudan [9]. Due to the spread
of multidrug-resistant P. falciparum malaria in Sudan
[10,11], artesunate plus sulfadoxine-pyrimethamine is
recommended as the first-line treatment for uncompli-
cated P. falciparum malaria. The study aimed to investigate
the efficacy of AS plus SP, as there is little published data
in Sudan [8,12].
Patients and methods
Data collection
The study was conducted in October and November, 2004
at four health centres in different regions of Sudan
(Damazin, Kassala, Kosti, and Malakal) (Figure 1). Three
of these areas were characterized by low malaria transmis-
sion and the fourth (Malakal) was characterized by stable
transmission [13]. Febrile (temperature ≥ 37.5°C)
patients with uncomplicated P. falciparum malaria [14],
who had no history of antimalarial drug use during the
preceding two weeks, were recruited for the study. Preg-
nant women and patients with mixed infections were
excluded.
After obtaining informed consent from the patient or the
child's parents, a fixed questionnaire including relevant
socio-demographic characteristics, medical history, phys-
ical findings and investigations conducted was completed
for each patient.
Laboratory methods
Blood films were prepared, stained with Giemsa and 100x
oil immersion fields were examined. The parasite density
was counted against 200 leucocytes, assuming 6,000 leu-
cocytes/µl. All the slides were double-checked blindly and
only considered negative if no parasites were detected in
100 oil immersion fields. If gametocytes were seen, then
the count was extended to 500 leucocytes.
Treatment and follow up
The patients were given the AS plus SP combination, with
artesunate (4 mg/kg. day) given on days 0–2 and a single
dose of SP (25 mg/kg) (Dafra Pharma, Beerse, Belgium)
given on day 0. The tablets were crushed and dissolved in
water for children who were not able to swallow them.
Subjects were observed for vomiting for one hour; the full
dose was repeated for those who vomited within 30 min
and half of the dose was repeated if vomiting occurred
between 30 and 60 minutes.
Follow-up and re-treatment
Patients were requested to come on days 1, 2, 3, 7, 14, 21
and 28 and at any time if they felt unwell. At each visit,
body temperature was measured and blood films were
prepared. During the follow-up the patients were asked if
they suffered from side effects which can be expected from
antimalarial treatment (nausea, vomiting, abdominal
pain, dizziness and rash); these symptoms were consid-
ered to be drug related if they had not been reported at the
patient's first presentation in the clinic.
Quinine was given for treatment failures. Early Treatment
Failures (ETF) in case of significant parasitaemia at day 2
or 3 or parasites and fever at day 3. Late Clinical Failures
(LCF) for cases with parasites and fever during follow-up
after day 3 and Late Parasitological Failures (LPF) for par-
asite infections with/without fever during the follow-up.
Cases which remained negative during follow-up were
considered Adequate Clinical and Parasitological
A sketch map of the Sudan, showing the main rivers, Khar- toum and the four sites where the study was conducted Figure 1
A sketch map of the Sudan, showing the main rivers, Khar-
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Responses (ACPR). These were modified WHO guidelines
[14,15].
Statistics
Data were entered into a computer database and SPSS
software (SPSS Inc., Chicago, IL, USA) was used for statis-
tical analysis. The means (age, weight, temperature and
parasite count) were calculated for all the patients and
were compared between the patients in the different loca-
tions using one way analysis of the variance (ANOVA),
when the data is normally distributed and by the Kruskal
Wallis test if the data was not normally distributed. Per-
centages were calculated and compared for the patients in
the four locations by an χ2 test. P < 0.05 was regarded
significant.
Ethical clearance
The study received ethical clearance from the Sudanese
National Malaria Administration.
Results
Two hundred and ninety (32.5%) out of 890 screened
patients fulfilled the criteria and were enrolled in the
study. Twenty-one (7.2%) of these were lost in the follow-
up and 269 patients (72, 50, 70, and 77 from Damazin,
Kassala, Kosti, and Malakal, respectively) completed the
28-day follow-up. Their different characteristics are
shown in Table 1. The mean age and weight were signifi-
cantly higher in the Kassala group. The parasite count was
significantly higher in the Malakal area. 37.0% (100
patients) were children less than five years old; this pro-
portion was significantly higher in Malakal group (92.2%,
see Table 1). One hundred and twenty seven subjects
(47.2%) were females; their percentages were not signifi-
cantly different within the groups (see Table 1).
On day one, 60 (22.3%) patients were febrile and 15
(5.5%) patients were parasitaemic. By day three all the
patients were afebrile and aparasitaemic. There were two
(0.7%) Late Clinical and Parasitological Failures (days 7
and 22) from Kassala, there was no Clinical and Parasito-
logical Failures from other locations (Table 2). Only one
patient (Kassala) showed gametocytaemia on day 14 of
the follow-up. Thirty two (11.9%) patients suffered
expected adverse effects (nausea, itching and dizziness),
but these were mild and resolved spontaneously.
Discussion
The study investigated the efficacy of AS plus SP for the
treatment of uncomplicated P. falciparum malaria at four
sites in the Sudan. This is probably the largest study
reporting AS plus SP efficacy in Sudan until now.
Although, the baseline characteristics (age and parasite
count) were significantly different between the four loca-
tions, the study showed that two (0.7%, Kassala) out of
269 patients were found to have Late Clinical and Parasi-
tological Failures. Since the parasite genotyping (PCR)
was not conducted, the possibility of re-infection/recru-
descence is still there. Hundred percent efficacy of AS plus
SP was recently reported from eastern Sudan [8] and 99%
from southern Sudan [12]. The high cure rate in this study
is comparable to that reported from neighbouring African
countries [5,6]. However, the highest drug resistant P. fal-
ciparum strains were reported from eastern Sudan [11,16].
The expected adverse effects (nausea, itching and dizzi-
ness) were reported in (11.9%) of the patients in this
study. These results were in line with, observations of oth-
ers, where the adverse effects were not significantly differ-
ent, if compared with those of SP alone [5,8].
The adverse effects (nausea, vomiting) might influence
the adherence to AS plus SP, especially science this ther-
apy is only available in the oral form, which is not the
medication preferred by Sudanese patients [17]. Further-
more, adherence may be influenced by the multiple doses
of the combination, rather the previous single dose of SP,
which was reported to be the most important single factor
for the best adherence of SP among Sudanese patients
[17].
A post- treatment gametocytaemia was detected in one
patient in Kassala area. High (20%) levels of gametocytae-
Table 1: The base line (day 0) characteristics of the 269 patients who completed the 28 days of follow-up after the treatment with 
artesunate plus sulfadoxine-pyrimethamine*.
Variable Total (N = 269) Damazin (N = 72) Kassala (N = 50)K o s t i  ( N = 70) Malakal (N = 77) Significance
Age, years 12.1 (12.4) 10.6 (9.0) 24.3 (15.4) 14.7 (12.08) 3.4 (1.2) P < 0.05
Weight, Kg 28.1 (19.3) 25.6 (14.5) 47.4 (21.5) 33.2 (18.5) 3.2 (0.36) P < 0.05
Temperature, °C 38.2 (0.76) 38.1 (0.6) 38.2 (0.6) 37.9 (0.5) 38.6 (0.9) P > 0.05
Parasite count, rings/µ 25532.3 (24196.2) 21924.3 (17748.7) 32240.3 (28372.9) 11509.8 (11135.2) 37297.5 (27844.5) P < 0.05
Children < 5 years 100 (37.0) 12 (16.7) 5 (10) 12 (17.1) 71 (92.2) P < 0.05
Female 127 (47.2) 37 (51.4) 18 (36) 32 (45.7) 40 (51.9) P > 0.05
*Data were shown as mean (SD) or numbers (%) as appropriateMalaria Journal 2005, 4:41 http://www.malariajournal.com/content/4/1/41
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mia had been reported in the eastern Sudan following SP,
quinine and mefloquine treatment [18-20]. However, it
has not been reported during the follow-up of patients in
the eastern Sudan treated with artemether, artesunate plus
mefloquine or AS plus SP [8,19,21]. The ability of artesu-
nate to reduce the post-treatment gametocytaemia is
important, as it may reduce transmission [4].
Conclusion
The study showed that, As plus SP is an effective, safe drug
in the treatment of uncomplicated P. falciparum malaria in
Sudan.
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Table 2: Trail profile, showing number of patients enrolled, treated and completing the 28 days of follow-up after the treatment with 
artesunate plus sulfadoxine-pyrimethamine*.
Variable Total Damazin Kassala Kosti Malakal
The recruited patients 290 77 53 76 84
Lost to follow-up 21 (7.2) 5 (6.5) 3 (5.6) 6 (7.9) 7 (8.3)
Patients completed the 28-days of follow-up 269 (94.8) 72 (93.5) 50 (94.4) 70 (92.1) 77 (91.7)
Accurate clinical and parasitological response 267 (99.3) 72 (100) 48 (96) 70 (100) 77 (100)
Late clinical and parasitological failure 2 (0.7) 0 (0) 2 (4) 0 (0) 0 (0)
*Data were shown as numbers (%).